Technical Analysis for PHAS - PhaseBio Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 2.98 -5.40% -0.17
PHAS closed down 5.4 percent on Wednesday, February 20, 2019, on 18 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical PHAS trend table...

Date Alert Name Type % Chg
Feb 20 180 Bearish Setup Bearish Swing Setup 0.00%
Feb 20 Narrow Range Bar Range Contraction 0.00%
Feb 20 Wide Bands Range Expansion 0.00%
Feb 20 Oversold Stochastic Weakness 0.00%
Feb 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -5.40%
Feb 19 Inside Day Range Contraction -5.40%
Feb 19 Wide Bands Range Expansion -5.40%
Feb 19 Oversold Stochastic Weakness -5.40%
Feb 15 Shooting Star Candlestick Bearish -0.67%
Feb 15 Wide Bands Range Expansion -0.67%

Older signals for PHAS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.
Biopharmaceutical Surgery Chemical Compounds Organic Compounds Pulmonary Arterial Hypertension Orphan Diseases Pulmonary Hypertension
Is PHAS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.0
52 Week Low 2.55
Average Volume 26,550
200-Day Moving Average 0.0
50-Day Moving Average 3.4346
20-Day Moving Average 3.2408
10-Day Moving Average 3.039
Average True Range 0.2454
ADX 14.15
+DI 14.1107
-DI 18.371
Chandelier Exit (Long, 3 ATRs ) 3.2338
Chandelier Exit (Short, 3 ATRs ) 3.6362
Upper Bollinger Band 3.7467
Lower Bollinger Band 2.7349
Percent B (%b) 0.24
BandWidth 31.220686
MACD Line -0.1436
MACD Signal Line -0.1317
MACD Histogram -0.0119
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.16
Resistance 3 (R3) 3.18 3.14 3.13
Resistance 2 (R2) 3.14 3.09 3.13 3.12
Resistance 1 (R1) 3.06 3.07 3.04 3.04 3.11
Pivot Point 3.02 3.02 3.01 3.01 3.02
Support 1 (S1) 2.94 2.97 2.92 2.92 2.85
Support 2 (S2) 2.90 2.95 2.89 2.84
Support 3 (S3) 2.82 2.90 2.83
Support 4 (S4) 2.80